<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Treatment of the carcinoid syndrome</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Treatment of the carcinoid syndrome</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Treatment of the carcinoid syndrome</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jonathan R Strosberg, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kenneth K Tanabe, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David C Whitcomb, MD, PhD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sonali M Shah, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Oct 19, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H624741546"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Carcinoid tumors are neuroendocrine tumors (NETs) that originate in the digestive tract, lungs, or rare primary sites, such as kidneys or ovaries. The term "carcinoid" usually implies a well-differentiated histology and is rarely used to describe high-grade or poorly differentiated neuroendocrine cancers. (See  <a class="medical medical_review" href="/d/html/14247.html" rel="external">"Pathology, classification, and grading of neuroendocrine neoplasms arising in the digestive system", section on 'Pathology, tumor classification, and nomenclature'</a>.)</p><p>Carcinoid syndrome is the term applied to a constellation of symptoms that are mediated by various hormones that are secreted by some NETs  (<a class="graphic graphic_table graphicRef79329" href="/d/graphic/79329.html" rel="external">table 1</a>) [<a href="#rid1">1</a>]. Two of the most common manifestations are flushing and diarrhea  (<a class="graphic graphic_table graphicRef63079" href="/d/graphic/63079.html" rel="external">table 2</a>). Symptoms are associated with elevations in serum serotonin or its metabolite urinary 5-hydroxyindoleacetic acid. More than 90 percent of patients with the carcinoid syndrome have metastatic disease, typically involving the liver, with primary tumors in the distal small intestine or proximal colon (midgut). (See  <a class="medical medical_review" href="/d/html/2614.html" rel="external">"Clinical features of carcinoid syndrome"</a>.)</p><p>By contrast, carcinoid crisis is a life-threatening form of carcinoid syndrome that results from the release of an overwhelming amount of biologically active compounds from the tumor that may be triggered by tumor manipulation (biopsy or surgery) or by anesthesia.</p><p>This topic provides an overview of treatment for patients with symptoms of the carcinoid syndrome, and recommendations for prevention and treatment of carcinoid crisis. Diagnosis of the carcinoid syndrome, radiologic staging, tumor localization, histologic assessment of NETs arising at different sites, and presentation, treatment, prognosis, and posttreatment surveillance of patients with localized and metastatic NETs are discussed separately. (See  <a class="medical medical_review" href="/d/html/2622.html" rel="external">"Diagnosis of carcinoid syndrome and tumor localization"</a> and  <a class="medical medical_review" href="/d/html/14247.html" rel="external">"Pathology, classification, and grading of neuroendocrine neoplasms arising in the digestive system", section on 'Pathology, tumor classification, and nomenclature'</a> and  <a class="medical medical_review" href="/d/html/2615.html" rel="external">"Staging, treatment, and post-treatment surveillance of non-metastatic, well-differentiated gastrointestinal tract neuroendocrine (carcinoid) tumors"</a> and  <a class="medical medical_review" href="/d/html/2194.html" rel="external">"Metastatic well-differentiated gastroenteropancreatic neuroendocrine tumors: Presentation, prognosis, imaging, and biochemical monitoring"</a> and  <a class="medical medical_review" href="/d/html/16105.html" rel="external">"Metastatic gastroenteropancreatic neuroendocrine tumors: Local options to control tumor growth and symptoms of hormone hypersecretion", section on 'Surgical resection'</a>.)</p><p class="headingAnchor" id="H1677916084"><span class="h1">INITIAL TREATMENT OF CARCINOID SYNDROME</span></p><p class="headingAnchor" id="H624742796"><span class="h2">Somatostatin-analog therapy</span><span class="headingEndMark"> — </span>Somatostatin is a 14-amino acid peptide that inhibits the secretion of a broad range of hormones. It acts by binding to somatostatin receptors, which are expressed on the majority of neuroendocrine tumors (NETs) [<a href="#rid2">2</a>]. Nearly 80 percent of well-differentiated gastrointestinal NETs express somatostatin receptors, as determined using somatostatin receptor-based diagnostic imaging with a radiolabeled form of the somatostatin analog <a class="drug drug_general" data-topicid="9714" href="/d/drug information/9714.html" rel="external">octreotide</a> (indium-111 [111-In] pentetreotide [OctreoScan]) or <a class="drug drug_general" data-topicid="108440" href="/d/drug information/108440.html" rel="external">gallium Ga-68 DOTATATE</a> (or gallium Ga-68 DOTATOC) positron emission tomography (PET)/computed tomography (CT). However, whether imaging with any of these modalities is necessary before a trial of somatostatin analog therapy for patients who are symptomatic from carcinoid syndrome is controversial. (See  <a class="medical medical_review" href="/d/html/2194.html" rel="external">"Metastatic well-differentiated gastroenteropancreatic neuroendocrine tumors: Presentation, prognosis, imaging, and biochemical monitoring", section on 'Somatostatin receptor-based imaging techniques'</a>.)</p><p>Because the somatostatin analogs <a class="drug drug_general" data-topicid="9714" href="/d/drug information/9714.html" rel="external">octreotide</a> and <a class="drug drug_general" data-topicid="10184" href="/d/drug information/10184.html" rel="external">lanreotide</a> bind to somatostatin receptors on the tumor cells, they are highly effective at inhibiting the release of serotonin and other vasoactive substances. Flushing and diarrhea are significantly improved in over 80 percent of patients with the carcinoid syndrome [<a href="#rid3">3</a>].</p><p>Treatment for symptomatic carcinoid syndrome may be initiated with short-acting <a class="drug drug_general" data-topicid="9714" href="/d/drug information/9714.html" rel="external">octreotide</a>, administered subcutaneously. An octreotide pen (2500 mcg/mL) for self- or caregiver administration of short-acting octreotide has been approved for initial treatment of severe diarrhea/flushing episodes associated with carcinoid syndrome. However, unless patients are severely symptomatic, we generally initiate therapy with octreotide long-acting release (LAR) rather than short-acting subcutaneous octreotide. We typically initiate depot octreotide (Sandostatin LAR) at a dose of 20 to 30 mg intramuscularly every four weeks [<a href="#rid4">4</a>].</p><p>Escalation of the dose or frequency of a somatostatin analog, or supplementation with doses of short-acting <a class="drug drug_general" data-topicid="9714" href="/d/drug information/9714.html" rel="external">octreotide</a> may be necessary for patients with refractory symptoms [<a href="#rid4">4,5</a>]. For example, patients who complain of exacerbation of symptoms at the end of their four-week somatostatin analog cycle may benefit from drug administration every three weeks. It is unclear whether there is benefit to escalation of dose beyond double the label dose. Typical doses of short-acting octreotide range from 200 to 500 mcg up to three times a day. Short-acting octreotide is also available in a prefilled pen at a concentration of 2500 mcg/mL.</p><p>A long-acting formulation of <a class="drug drug_general" data-topicid="10184" href="/d/drug information/10184.html" rel="external">lanreotide</a> (Somatuline Depot) is also available for monthly injections at doses ranging from 60 to 120 mg every four weeks [<a href="#rid6">6</a>]. Lanreotide appears to have similar clinical efficacy and tolerability as <a class="drug drug_general" data-topicid="9714" href="/d/drug information/9714.html" rel="external">octreotide</a> for treatment of the carcinoid syndrome [<a href="#rid7">7-14</a>]. In a randomized phase III trial of depot lanreotide versus placebo in patients with carcinoid syndrome, lanreotide significantly reduced the need for short-acting somatostatin analog injections compared with placebo [<a href="#rid13">13,14</a>].</p><p>Both <a class="drug drug_general" data-topicid="9714" href="/d/drug information/9714.html" rel="external">octreotide</a> and <a class="drug drug_general" data-topicid="10184" href="/d/drug information/10184.html" rel="external">lanreotide</a> are usually well tolerated. Rarely, patients may develop nausea, abdominal discomfort, bloating and/or steatorrhea, often during the first several weeks of therapy, after which the symptoms subside. Pancreatic malabsorption may be a contributing factor, which can be alleviated with pancreatic enzyme supplementation. Another effect of somatostatin analogs is inhibition of gallbladder contractility, which can lead to gallstones or sludge. For that reason, a prophylactic cholecystectomy is sometimes recommended for patients who are undergoing abdominal surgery for other reasons [<a href="#rid15">15</a>].</p><p class="headingAnchor" id="H945119"><span class="h3">Antiproliferative effects</span><span class="headingEndMark"> — </span>The somatostatin analogs <a class="drug drug_general" data-topicid="9714" href="/d/drug information/9714.html" rel="external">octreotide</a> and <a class="drug drug_general" data-topicid="10184" href="/d/drug information/10184.html" rel="external">lanreotide</a> were initially developed for control of the carcinoid syndrome. Both drugs have also been proven to inhibit tumor growth in randomized phase III trials [<a href="#rid16">16,17</a>]. This subject is addressed separately. (See  <a class="medical medical_review" href="/d/html/16901.html" rel="external">"Metastatic well-differentiated gastrointestinal neuroendocrine (carcinoid) tumors: Systemic therapy options to control tumor growth", section on 'Somatostatin analogs'</a> and  <a class="medical medical_review" href="/d/html/16901.html" rel="external">"Metastatic well-differentiated gastrointestinal neuroendocrine (carcinoid) tumors: Systemic therapy options to control tumor growth"</a>.)</p><p class="headingAnchor" id="H945488"><span class="h2">Liver-directed therapies</span><span class="headingEndMark"> — </span>Hepatic resection is often considered for the treatment of potentially resectable liver metastases in the absence of diffuse bilobar involvement, compromised liver function, or widespread extrahepatic metastases. Hepatic resection can also provide palliation for patients who are symptomatic from tumor bulk or the carcinoid syndrome. Preoperative and intraoperative <a class="drug drug_general" data-topicid="9714" href="/d/drug information/9714.html" rel="external">octreotide</a> therapy are essential to protect against carcinoid crises that can arise from anesthesia and/or tumor manipulation. (See <a class="local">'Carcinoid crisis: prevention and management'</a> below.)</p><p>Hepatic resections are generally restricted to patients in whom 90 percent or more of the disease bulk can be successfully resected or ablated. These issues are all addressed in more detail separately. (See  <a class="medical medical_review" href="/d/html/16105.html" rel="external">"Metastatic gastroenteropancreatic neuroendocrine tumors: Local options to control tumor growth and symptoms of hormone hypersecretion", section on 'Surgical resection'</a>.)</p><p>Hepatic transarterial embolizations are often performed for patients with surgically unresectable liver-dominant metastases. In patients with widespread liver metastases, the embolizations are often lobar rather than highly selective. Embolization of the entire liver can usually be undertaken in two to three separate procedures. In uncontrolled trials, up to 75 percent of patients with neuroendocrine tumor hepatic metastases have marked symptomatic improvement in flushing and diarrhea [<a href="#rid18">18-21</a>]. Embolizations can be performed using microparticles alone (bland embolization) or with admixed chemotherapy (chemoembolization). There is no evidence that chemoembolization results in superior outcomes compared with bland embolization, particularly in the treatment of metastases from midgut NETs, which are generally chemoresistant (as compared with pancreatic NETs). Short-term side effects of liver embolization include abdominal pain, fever, nausea/vomiting, and fatigue. Patients with the carcinoid syndrome should receive prophylactic <a class="drug drug_general" data-topicid="9714" href="/d/drug information/9714.html" rel="external">octreotide</a> pre- and postembolization in order to reduce risk of carcinoid crisis.</p><p>Experience with radioembolization using yttrium-90 (<sup>90</sup>Y)-labeled resin or glass microspheres is limited but growing. Radioembolization using <sup>90</sup>Y-labeled resin or glass microspheres reduces symptoms in approximately one-half of patients with functioning NETs [<a href="#rid22">22,23</a>]. However, in the absence of randomized trials, it is difficult to know when to choose this technique over other embolization techniques. In particular, the risk of long-term radioembolization-induced liver disease (REILD) has not been well-characterized. (See  <a class="medical medical_review" href="/d/html/16105.html" rel="external">"Metastatic gastroenteropancreatic neuroendocrine tumors: Local options to control tumor growth and symptoms of hormone hypersecretion", section on 'Hepatic arterial embolization'</a>.)</p><p class="headingAnchor" id="H624742803"><span class="h1">MANAGEMENT OF REFRACTORY SYMPTOMS</span></p><p class="headingAnchor" id="H153891696"><span class="h2">Telotristat</span><span class="headingEndMark"> — </span>The carcinoid syndrome is thought to be caused in large part by secretion of serotonin. A rate-limiting step in the conversion of the amino acid tryptophan to serotonin is mediated by the enzyme tryptophan hydroxylase  (<a class="graphic graphic_figure graphicRef51368" href="/d/graphic/51368.html" rel="external">figure 1</a>). An oral tryptophan hydroxylase inhibitor, <a class="drug drug_general" data-topicid="112170" href="/d/drug information/112170.html" rel="external">telotristat</a> ethyl, can be used in combination with somatostatin analog therapy in order to control diarrhea associated with the carcinoid syndrome. Approval was based on the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT01677910%3Fterm%3DTelestar%26rank%3D1&amp;token=nbsXe3i4qfUea5RCPRHtOS7yhoEzH%2BMCpwZ1%2F1ekxPPxhoOZyNqfWlqF4haapN66l2pJ4Lyx3SH%2FJTgrCTaq3mC3qTeS6EgH2yU9rVWyKY8%3D&amp;TOPIC_ID=16638" target="_blank">TELESTAR trial</a>, a three-arm study evaluating two doses of oral telotristat (250 mg and 500 mg, each taken three times daily) against placebo over a 12-week period) that was conducted in 135 patients with history of carcinoid syndrome who were receiving treatment with a somatostatin analog and who had uncontrolled diarrhea (≥4 bowel movements daily) [<a href="#rid24">24</a>]. Treatment with telotristat at either dose was associated with a statistically significant reduction in bowel movement frequency over time compared with placebo. At week 12, the arithmetic mean reduction in daily bowel movement frequency from baseline was -1.7 and -2.1 with telotristat 250 and 500 mg, respectively, compared with -0.9 for placebo. Urinary 5-hydroxyindoleacetic acid (5-HIAA; a metabolite of serotonin) was also significantly decreased with telotristat; by week 12, mean urinary 5-HIAA levels decreased by 40 and 57.7 mg per 24 hours with telotristat 250 and 500 mg, respectively, while levels increased in the placebo group by 11.5 mg per 24 hours in this same time period. Too few patients had flushing or abdominal discomfort to ascertain changes in these endpoints. Overall, the drug was well tolerated. There was a higher incidence of nausea with the 500 mg dose of telotristat as compared with either the lower 250 mg dose or placebo (31 versus 13 and 11 percent, respectively), and depression-related adverse events were also more frequent at the higher dose (16 versus 7 percent each for the telotristat 250 mg and placebo groups, respectively).</p><p>Largely based upon these results, <a class="drug drug_general" data-topicid="112170" href="/d/drug information/112170.html" rel="external">telotristat</a> has been approved in the United States in combination with somatostatin analog therapy for the treatment of adults with diarrhea related to carcinoid syndrome that is inadequately controlled by somatostatin analog therapy alone [<a href="#rid25">25</a>]. The recommended dose is 250 mg three times daily with food [<a href="#rid26">26</a>].</p><p>Flushing in patients with carcinoid syndrome is associated with production of multiple vasoactive substances, and it is unclear whether <a class="drug drug_general" data-topicid="112170" href="/d/drug information/112170.html" rel="external">telotristat</a> has a significant impact upon this symptom. On the other hand, carcinoid heart disease is thought to be directly related to high levels of circulating serotonin. Although evidence of inhibition of carcinoid heart disease with telotristat is purely anecdotal at this time, use of the drug in patients with early evidence of carcinoid heart disease and high levels of circulating serotonin is reasonable, even if their diarrhea is otherwise controlled.</p><p class="headingAnchor" id="H945210"><span class="h2">Interferon</span><span class="headingEndMark"> — </span>Another option for control of refractory symptoms of the carcinoid syndrome in patients treated with somatostatin analogs is interferon alfa (IFNa) [<a href="#rid27">27</a>]. Interferons can exert antitumor effects via stimulation of T cells, induction of cell cycle arrest, and inhibition of angiogenesis.</p><p>In retrospective series, low-dose IFNa alone (ie, 3 to 5 million units up to three to five times weekly) reduces symptoms of hormonal hypersecretion (flushing, diarrhea) in 40 to 50 percent of patients who are refractory to somatostatin analogs [<a href="#rid28">28</a>]. Objective tumor regression is rare [<a href="#rid29">29</a>]. Unfortunately, the benefits of IFNa for neuroendocrine tumors (NETs) are counterbalanced by sometimes debilitating toxicities, which can include fatigue, depression, and flu-like symptoms. As a result, IFNa is rarely used and typically only for otherwise refractory NETs. (See  <a class="medical medical_review" href="/d/html/16901.html" rel="external">"Metastatic well-differentiated gastrointestinal neuroendocrine (carcinoid) tumors: Systemic therapy options to control tumor growth", section on 'Interferon'</a>.)</p><p class="headingAnchor" id="H944956"><span class="h2">Antidiarrheal therapy</span><span class="headingEndMark"> — </span>Antidiarrheal agents, such as <a class="drug drug_general" data-topicid="9571" href="/d/drug information/9571.html" rel="external">loperamide</a> and/or <a class="drug drug_general" data-topicid="9370" href="/d/drug information/9370.html" rel="external">diphenoxylate-atropine</a> (Lomotil), can be used for control of refractory diarrhea. For more severe diarrhea, the opiates <a class="drug drug_general" data-topicid="9740" href="/d/drug information/9740.html" rel="external">paregoric</a> (where available) and <a class="drug drug_general" data-topicid="9721" href="/d/drug information/9721.html" rel="external">tincture of opium</a> may be prescribed. Paregoric has been discontinued in the United States but is available in other countries. A few reports demonstrate that serotonin receptor antagonists, such as <a class="drug drug_general" data-topicid="9719" href="/d/drug information/9719.html" rel="external">ondansetron</a>, can alleviate diarrhea in patients with the carcinoid syndrome in whom treatment with somatostatin analogs is not successful [<a href="#rid30">30-32</a>].</p><p>Other causes of diarrhea should be considered. As noted above, symptomatic fat malabsorption and steatorrhea from chronic somatostatin analog therapy may respond to pancreatic enzyme supplementation. (See <a class="local">'Somatostatin-analog therapy'</a> above.)</p><p>Patients who have undergone resection of the distal small bowel frequently develop bile malabsorption and bile salt-induced diarrhea that can be treated with bile acid sequestrants, such as <a class="drug drug_general" data-topicid="9258" href="/d/drug information/9258.html" rel="external">cholestyramine</a> or <a class="drug drug_general" data-topicid="9294" href="/d/drug information/9294.html" rel="external">colestipol</a> [<a href="#rid33">33</a>]. A trial of a bile acid sequestrant is reasonable in any patient who has refractory diarrhea after right hemicolectomy.</p><p class="headingAnchor" id="H945796"><span class="h2">Systemic therapies</span></p><p class="headingAnchor" id="H2093580290"><span class="h3">Everolimus</span><span class="headingEndMark"> — </span>There are few data addressing the benefit of <a class="drug drug_general" data-topicid="9078" href="/d/drug information/9078.html" rel="external">everolimus</a>, a mechanistic (previously called mammalian) target of rapamycin (mTOR) inhibitor, for control of symptoms related to carcinoid syndrome. Most of the information comes from small retrospective series and case reports [<a href="#rid34">34,35</a>]. It is important to note that diarrhea is a frequent side effect of everolimus.</p><p>In the phase III RADIANT 2 study comparing <a class="drug drug_general" data-topicid="9078" href="/d/drug information/9078.html" rel="external">everolimus</a> plus <a class="drug drug_general" data-topicid="9714" href="/d/drug information/9714.html" rel="external">octreotide</a> long-acting release (LAR) with placebo plus octreotide LAR in patients with metastatic NETs and a history of carcinoid syndrome, improvements in urinary excretion of 5-HIAA occurred at a slightly higher frequency in the everolimus arm of this study (61 versus 54 percent), but information was not provided on symptoms attributed to carcinoid syndrome [<a href="#rid36">36</a>]. The study fell short of meeting its primary endpoint, which was a significant improvement in progression-free survival with everolimus. (See  <a class="medical medical_review" href="/d/html/16901.html" rel="external">"Metastatic well-differentiated gastrointestinal neuroendocrine (carcinoid) tumors: Systemic therapy options to control tumor growth", section on 'Molecularly targeted therapy'</a>.)</p><p class="headingAnchor" id="H945282"><span class="h2">177-Lutetium (Lu) dotatate (Peptide receptor radioligand therapy)</span><span class="headingEndMark"> — </span>Radiolabeled somatostatin analogs can be used to deliver targeted radiation to somatostatin receptor-expressing tumors. Single-arm studies of the radiolabeled somatostatin analogs have demonstrated high symptomatic response rates in patients with carcinoid syndrome who were refractory to <a class="drug drug_general" data-topicid="9714" href="/d/drug information/9714.html" rel="external">octreotide</a> [<a href="#rid37">37</a>].</p><p>The phase III NETTER-1 study randomized 231 patients with progressive metastatic midgut NETs to receive 177-Lu-dotatate plus <a class="drug drug_general" data-topicid="9714" href="/d/drug information/9714.html" rel="external">octreotide</a> LAR 30 mg versus high-dose octreotide (60 mg every four weeks). Analysis of health-related quality of life (HRQOL) outcomes based on European Organisation for Research and Treatment of Cancer (EORTC) questionnaires demonstrated clinically and statistically significant delays in time to deterioration of HRQOL in global health, physical functioning, role functioning, and in clinically relevant symptoms, notably diarrhea [<a href="#rid38">38</a>]. No significant change was seen in time to deterioration of flushing. (See  <a class="medical medical_review" href="/d/html/2194.html" rel="external">"Metastatic well-differentiated gastroenteropancreatic neuroendocrine tumors: Presentation, prognosis, imaging, and biochemical monitoring", section on 'Somatostatin receptor-based imaging techniques'</a> and  <a class="medical medical_review" href="/d/html/90664.html" rel="external">"Metastatic well-differentiated pancreatic neuroendocrine tumors: Systemic therapy options to control tumor growth and symptoms of hormone hypersecretion", section on 'Radiolabeled somatostatin analogs'</a> and  <a class="medical medical_review" href="/d/html/16901.html" rel="external">"Metastatic well-differentiated gastrointestinal neuroendocrine (carcinoid) tumors: Systemic therapy options to control tumor growth", section on 'Radiolabeled somatostatin analogs'</a>.)</p><p class="headingAnchor" id="H1042251769"><span class="h1">CARCINOID HEART DISEASE</span><span class="headingEndMark"> — </span>Carcinoid heart disease occurs in fewer than one-half of patients with the carcinoid syndrome. High-circulating concentrations of serotonin are thought to be the major underlying factor. Carcinoid heart lesions are characterized by plaque-like fibrous endocardial thickening that classically involves the right side of the heart, and often causes retraction and fixation of the leaflets of the tricuspid and pulmonary valves  (<a class="graphic graphic_picture graphicRef77192" href="/d/graphic/77192.html" rel="external">picture 1</a>). Tricuspid regurgitation is a nearly universal finding; tricuspid stenosis, pulmonary regurgitation, and pulmonary stenosis may also occur. The resulting right-sided heart failure produces significant morbidity and mortality. (See  <a class="medical medical_review" href="/d/html/8135.html" rel="external">"Carcinoid heart disease", section on 'Clinical manifestations'</a>.)</p><p>Among patients with the carcinoid syndrome, individuals with carcinoid heart disease exhibit higher levels of serum serotonin and urinary 5-hydroxyindoleacetic acid excretion than do those without heart disease. (See  <a class="medical medical_review" href="/d/html/8135.html" rel="external">"Carcinoid heart disease", section on 'Pathophysiology'</a>.)</p><p>Because evidence suggests a pathogenic role for serotonin or one of its metabolites in the development of carcinoid heart disease, it is likely that somatostatin analogs and other therapies that reduce circulating serotonin levels can reduce the risk of developing carcinoid heart disease, and they may inhibit progression of existing disease. However, there is no evidence that medical therapy of carcinoid syndrome can reverse valvular damage. (See  <a class="medical medical_review" href="/d/html/8135.html" rel="external">"Carcinoid heart disease", section on 'Treatment of carcinoid syndrome'</a>.)</p><p>Guidelines for screening for carcinoid heart disease in at-risk patients without valvular heart disease or heart failure are evolving, with differing recommendations in various major society guidelines [<a href="#rid39">39</a>]. For most patients with carcinoid syndrome, periodic echocardiography is recommended, although the optimal frequency is not established. Another alternative is monitoring of serum levels of N-terminal brain natriuretic peptide. This subject is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/8135.html" rel="external">"Carcinoid heart disease", section on 'When and how to initially test for carcinoid heart disease'</a>.)</p><p>Management of patients with diagnosed carcinoid heart disease is discussed separately. (See  <a class="medical medical_review" href="/d/html/8135.html" rel="external">"Carcinoid heart disease", section on 'Valve intervention'</a>.)</p><p class="headingAnchor" id="H624742810"><span class="h1">CARCINOID CRISIS: PREVENTION AND MANAGEMENT</span><span class="headingEndMark"> — </span>Carcinoid crisis is a life-threatening form of the carcinoid syndrome that may be triggered by tumor manipulation (eg biopsy, surgery) or by anesthesia [<a href="#rid40">40</a>]. It is less commonly reported after chemotherapy, hepatic arterial embolization, or radionuclide therapy, mostly in patients with extensive tumor bulk [<a href="#rid41">41-48</a>].</p><p>Carcinoid crisis results from the release of an overwhelming amount of biologically active compounds from the tumor  (<a class="graphic graphic_table graphicRef79329" href="/d/graphic/79329.html" rel="external">table 1</a>). The predominant symptom is wide blood pressure fluctuations with a predominance of hypotension.</p><p><a class="drug drug_general" data-topicid="9714" href="/d/drug information/9714.html" rel="external">Octreotide</a> should be available during any surgical procedure, particularly the resection of hepatic metastases. Until recently, prophylactic administration of octreotide prior to resection (300 to 500 mcg intravenously or subcutaneously) was routinely recommended to reduce the incidence of carcinoid crisis in patients with a history of carcinoid syndrome who require surgical procedures [<a href="#rid49">49-52</a>]. However, intraoperative complications can still occur despite the use of preoperative prophylactic octreotide, and the routine use of prophylactic octreotide has been called into question [<a href="#rid53">53</a>]. In this report of 195 operations (primarily bowel and/or hepatic metastasis resection) on 171 patients with NETs with no prophylactic octreotide, an intraoperative carcinoid crisis developed in only 49 operations (25 percent), and was predominantly characterized by profound hypotension and tachycardia. Patients were managed with intravenous (IV) fluids and vasopressors, the duration of each episode was short (median duration of the first episode three minutes, and of the second episode two minutes), and there were no postoperative complications associated with the development of carcinoid crisis. Citing these data and other studies demonstrating a lack of benefit for preoperative octreotide in preventing intraoperative carcinoid crisis [<a href="#rid49">49,54-56</a>], the authors concluded that use of prophylactic octreotide may be safely discontinued and that treatment of crisis with octreotide should be replaced with intravenous fluids and vasopressors.</p><p>In our view, prophylactic preoperative use of <a class="drug drug_general" data-topicid="9714" href="/d/drug information/9714.html" rel="external">octreotide</a> is optional in patients with carcinoid syndrome (especially in patients who are already receiving a long-acting somatostatin analog), and is almost certainly unnecessary in patients without carcinoid syndrome. We recommend that octreotide be available intraoperatively for "as needed" intravenous use for patients with carcinoid syndrome who develop hemodynamic instability during surgery. Doses of 500 mcg can be used IV, potentially followed by an IV infusion of 50 to 200 mcg per hour.</p><p class="headingAnchor" id="H2274811982"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/111962.html" rel="external">"Society guideline links: Well-differentiated gastroenteropancreatic neuroendocrine tumors"</a>.)</p><p class="headingAnchor" id="H2324996005"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/d/html/86735.html" rel="external">"Patient education: Carcinoid syndrome (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H624743869"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definitions</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Carcinoid syndrome is the term applied to a constellation of symptoms mediated by various hormones that are elaborated by some neuroendocrine tumors (NETs)  (<a class="graphic graphic_table graphicRef79329" href="/d/graphic/79329.html" rel="external">table 1</a>) [<a href="#rid1">1</a>]. Two of the most common manifestations are flushing and diarrhea  (<a class="graphic graphic_table graphicRef63079" href="/d/graphic/63079.html" rel="external">table 2</a>). More than 90 percent of patients with the carcinoid syndrome have metastatic disease, typically to the liver, and primary tumors in the midgut. (See  <a class="medical medical_review" href="/d/html/2614.html" rel="external">"Clinical features of carcinoid syndrome"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Carcinoid crisis is a life-threatening form of carcinoid syndrome that results from the release of an overwhelming amount of biologically active compounds from the tumor; it may be triggered by tumor manipulation (eg, biopsy, embolization, surgery) or anesthesia, and occurs mostly in patients with markedly elevated serum serotonin or urine 5-hydroxyindoleacetic acid. (See <a class="local">'Carcinoid crisis: prevention and management'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initial treatment of carcinoid syndrome</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The somatostatin analogs <a class="drug drug_general" data-topicid="9714" href="/d/drug information/9714.html" rel="external">octreotide</a> and <a class="drug drug_general" data-topicid="10184" href="/d/drug information/10184.html" rel="external">lanreotide</a> are highly effective in controlling the symptoms associated with NETs. For patients who are symptomatic from carcinoid syndrome, we recommend initiating treatment with a somatostatin analog (<a class="grade" href="https://medilib.ir/uptodate/show/grade_1" rel="external">Grade 1A</a>). (See <a class="local">'Somatostatin-analog therapy'</a> above.)</p><p></p><p class="bulletIndent2">We usually begin therapy with <a class="drug drug_general" data-topicid="9714" href="/d/drug information/9714.html" rel="external">octreotide</a> long-acting release (LAR) 30 mg every four weeks or depot <a class="drug drug_general" data-topicid="10184" href="/d/drug information/10184.html" rel="external">lanreotide</a> 120 mg every four weeks; however, lower starting doses can be considered (eg, octreotide 20 mg or lanreotide 90 mg).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Liver-directed therapies, including surgical resection or hepatic embolization, can be highly palliative for patients with carcinoid syndrome and liver-dominant disease. (See <a class="local">'Liver-directed therapies'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management of refractory disease</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients with persistence or recurrence of flushing and/or diarrhea may benefit from higher doses or more frequent administration of long-acting somatostatin analogs. (See <a class="local">'Management of refractory symptoms'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with somatostatin receptor expressing tumors, one option is radiolabeled somatostatin analog 177-Lutetium Dotatate, which is associated with high symptomatic response rates in patients with carcinoid syndrome who were refractory to <a class="drug drug_general" data-topicid="9714" href="/d/drug information/9714.html" rel="external">octreotide</a>. (See <a class="local">'177-Lutetium (Lu) dotatate (Peptide receptor radioligand therapy)'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients with refractory diarrhea may benefit from use of an antidiarrheal agent, such as <a class="drug drug_general" data-topicid="9571" href="/d/drug information/9571.html" rel="external">loperamide</a>. (See <a class="local">'Antidiarrheal therapy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with carcinoid syndrome diarrhea that is refractory to somatostatin analog therapy and other treatments, we suggest <a class="drug drug_general" data-topicid="112170" href="/d/drug information/112170.html" rel="external">telotristat</a> (<a class="grade" href="https://medilib.ir/uptodate/show/grade_4" rel="external">Grade 2A</a>). (See <a class="local">'Telotristat'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Carcinoid heart disease</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Carcinoid heart disease can occur in patients with severe, longstanding elevations of circulating serotonin and is typically characterized by fibrosis of the right-sided (tricuspid and pulmonary) heart valves.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The available evidence suggests a pathogenic role for serotonin or one of its metabolites in the development of carcinoid heart disease, and it is likely that somatostatin analogs and other therapies that reduce circulating serotonin levels can reduce the risk of developing carcinoid heart disease, and possibly inhibit progression of existing disease. However, there is no evidence that medical therapy of carcinoid syndrome can reverse valvular damage. (See <a class="local">'Carcinoid heart disease'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prevention and treatment of carcinoid crisis</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients undergoing surgery for metastatic NET who have a history of carcinoid syndrome, prophylactic preoperative use of <a class="drug drug_general" data-topicid="9714" href="/d/drug information/9714.html" rel="external">octreotide</a> is optional, especially in those who are already receiving a long-acting somatostatin analog, and is almost certainly unnecessary in patients without carcinoid syndrome. (See <a class="local">'Carcinoid crisis: prevention and management'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9714" href="/d/drug information/9714.html" rel="external">Octreotide</a> should be available intraoperatively for "as needed" intravenous use for patients with carcinoid syndrome who develop hemodynamic instability during surgery. Doses of 500 mcg can be used intravenously (IV), potentially followed by an IV infusion of 50 to 200 mcg per hour.</p><p></p><p><strong>ACKNOWLEDGMENT</strong> — The UpToDate editorial staff acknowledges Stephen Goldfinger, MD, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Kulke MH, Mayer RJ. Carcinoid tumors. N Engl J Med 1999; 340:858.</a></li><li><a class="nounderline abstract_t">Reubi JC, Kvols LK, Waser B, et al. Detection of somatostatin receptors in surgical and percutaneous needle biopsy samples of carcinoids and islet cell carcinomas. Cancer Res 1990; 50:5969.</a></li><li><a class="nounderline abstract_t">Kvols LK, Moertel CG, O'Connell MJ, et al. Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue. N Engl J Med 1986; 315:663.</a></li><li><a class="nounderline abstract_t">Rubin J, Ajani J, Schirmer W, et al. Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome. J Clin Oncol 1999; 17:600.</a></li><li><a class="nounderline abstract_t">Strosberg J, Weber J, Feldman M, et al. Above-Label Doses of Octreotide-LAR in Patients With Metastatic Small Intestinal Carcinoid Tumors. Gastrointest Cancer Res 2013; 6:81.</a></li><li><a class="nounderline abstract_t">Ruszniewski P, Ducreux M, Chayvialle JA, et al. Treatment of the carcinoid syndrome with the longacting somatostatin analogue lanreotide: a prospective study in 39 patients. Gut 1996; 39:279.</a></li><li><a class="nounderline abstract_t">Faiss S, Räth U, Mansmann U, et al. Ultra-high-dose lanreotide treatment in patients with metastatic neuroendocrine gastroenteropancreatic tumors. Digestion 1999; 60:469.</a></li><li><a class="nounderline abstract_t">Wymenga AN, Eriksson B, Salmela PI, et al. Efficacy and safety of prolonged-release lanreotide in patients with gastrointestinal neuroendocrine tumors and hormone-related symptoms. J Clin Oncol 1999; 17:1111.</a></li><li><a class="nounderline abstract_t">O'Toole D, Ducreux M, Bommelaer G, et al. Treatment of carcinoid syndrome: a prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance. Cancer 2000; 88:770.</a></li><li><a class="nounderline abstract_t">Ducreux M, Ruszniewski P, Chayvialle JA, et al. The antitumoral effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumors. Am J Gastroenterol 2000; 95:3276.</a></li><li><a class="nounderline abstract_t">Faiss S, Pape UF, Böhmig M, et al. Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors--the International Lanreotide and Interferon Alfa Study Group. J Clin Oncol 2003; 21:2689.</a></li><li><a class="nounderline abstract_t">Khan MS, El-Khouly F, Davies P, et al. Long-term results of treatment of malignant carcinoid syndrome with prolonged release Lanreotide (Somatuline Autogel). Aliment Pharmacol Ther 2011; 34:235.</a></li><li><a class="nounderline abstract_t">Vinik AI, Wolin EM, Liyanage N, et al. EVALUATION OF LANREOTIDE DEPOT/AUTOGEL EFFICACY AND SAFETY AS A CARCINOID SYNDROME TREATMENT (ELECT): A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL. Endocr Pract 2016; 22:1068.</a></li><li><a class="nounderline abstract_t">Fisher GA Jr, Wolin EM, Liyanage N, et al. Patient-Reported Symptom Control of Diarrhea and Flushing in Patients with Neuroendocrine Tumors Treated with Lanreotide Depot/Autogel: Results from a Randomized, Placebo-Controlled, Double-Blind and 32-Week Open-Label Study. Oncologist 2018; 23:16.</a></li><li><a class="nounderline abstract_t">Strosberg JR, Cheema A, Kvols LK. A review of systemic and liver-directed therapies for metastatic neuroendocrine tumors of the gastroenteropancreatic tract. Cancer Control 2011; 18:127.</a></li><li><a class="nounderline abstract_t">Rinke A, Müller HH, Schade-Brittinger C, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 2009; 27:4656.</a></li><li><a class="nounderline abstract_t">Caplin ME, Pavel M, Ćwikła JB, et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med 2014; 371:224.</a></li><li><a class="nounderline abstract_t">Ruszniewski P, Malka D. Hepatic arterial chemoembolization in the management of advanced digestive endocrine tumors. Digestion 2000; 62 Suppl 1:79.</a></li><li><a class="nounderline abstract_t">Strosberg JR, Choi J, Cantor AB, Kvols LK. Selective hepatic artery embolization for treatment of patients with metastatic carcinoid and pancreatic endocrine tumors. Cancer Control 2006; 13:72.</a></li><li><a class="nounderline abstract_t">Gupta S, Yao JC, Ahrar K, et al. Hepatic artery embolization and chemoembolization for treatment of patients with metastatic carcinoid tumors: the M.D. Anderson experience. Cancer J 2003; 9:261.</a></li><li><a class="nounderline abstract_t">Eriksson BK, Larsson EG, Skogseid BM, et al. Liver embolizations of patients with malignant neuroendocrine gastrointestinal tumors. Cancer 1998; 83:2293.</a></li><li><a class="nounderline abstract_t">King J, Quinn R, Glenn DM, et al. Radioembolization with selective internal radiation microspheres for neuroendocrine liver metastases. Cancer 2008; 113:921.</a></li><li><a class="nounderline abstract_t">Cao CQ, Yan TD, Bester L, et al. Radioembolization with yttrium microspheres for neuroendocrine tumour liver metastases. Br J Surg 2010; 97:537.</a></li><li><a class="nounderline abstract_t">Kulke MH, Hörsch D, Caplin ME, et al. Telotristat Ethyl, a Tryptophan Hydroxylase Inhibitor for the Treatment of Carcinoid Syndrome. J Clin Oncol 2017; 35:14.</a></li><li class="breakAll">https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm544035.htm (Accessed on March 03, 2017).</li><li class="breakAll">http://www.xermelo.com/Media/Default/pdfs/Product_Info_telotristat_etiprate.pdf (Accessed on March 03, 2017).</li><li><a class="nounderline abstract_t">Oberg K, Funa K, Alm G. Effects of leukocyte interferon on clinical symptoms and hormone levels in patients with mid-gut carcinoid tumors and carcinoid syndrome. N Engl J Med 1983; 309:129.</a></li><li><a class="nounderline abstract_t">Frank M, Klose KJ, Wied M, et al. Combination therapy with octreotide and alpha-interferon: effect on tumor growth in metastatic endocrine gastroenteropancreatic tumors. Am J Gastroenterol 1999; 94:1381.</a></li><li><a class="nounderline abstract_t">Yao JC, Guthrie K, Moran C, et al. SWOG S0518: Phase III prospective randomized comparison of depot octreotide plus interferon alpha-2b versus depot octreotide plus bevacizumab (NSC #704865) in advanced, poor prognosis carcinoid patients (NCT00569127). J Clin Oncol 2015; 33S: ASCO #4004.</a></li><li><a class="nounderline abstract_t">Wymenga AN, de Vries EG, Leijsma MK, et al. Effects of ondansetron on gastrointestinal symptoms in carcinoid syndrome. Eur J Cancer 1998; 34:1293.</a></li><li><a class="nounderline abstract_t">Kiesewetter B, Raderer M. Ondansetron for diarrhea associated with neuroendocrine tumors. N Engl J Med 2013; 368:1947.</a></li><li><a class="nounderline abstract_t">Kiesewetter B, Duan H, Lamm W, et al. Oral Ondansetron Offers Effective Antidiarrheal Activity for Carcinoid Syndrome Refractory to Somatostatin Analogs. Oncologist 2019; 24:255.</a></li><li><a class="nounderline abstract_t">Westergaard H. Bile Acid malabsorption. Curr Treat Options Gastroenterol 2007; 10:28.</a></li><li><a class="nounderline abstract_t">Bainbridge HE, Larbi E, Middleton G. Symptomatic Control of Neuroendocrine Tumours with Everolimus. Horm Cancer 2015; 6:254.</a></li><li><a class="nounderline abstract_t">Capdevila J, Díez Miranda I, Obiols G, Tabernero J. Control of carcinoid syndrome with everolimus. Ann Oncol 2011; 22:237.</a></li><li><a class="nounderline abstract_t">Pavel ME, Hainsworth JD, Baudin E, et al. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet 2011; 378:2005.</a></li><li><a class="nounderline abstract_t">Bushnell DL Jr, O'Dorisio TM, O'Dorisio MS, et al. 90Y-edotreotide for metastatic carcinoid refractory to octreotide. J Clin Oncol 2010; 28:1652.</a></li><li><a class="nounderline abstract_t">Strosberg J, Wolin E, Chasen B, et al. Health-Related Quality of Life in Patients With Progressive Midgut Neuroendocrine Tumors Treated With 177Lu-Dotatate in the Phase III NETTER-1 Trial. J Clin Oncol 2018; 36:2578.</a></li><li><a class="nounderline abstract_t">Dobson R, Valle JW, Burgess MI, et al. Variation in Cardiac Screening and Management of Carcinoid Heart Disease in the UK and Republic of Ireland. Clin Oncol (R Coll Radiol) 2015; 27:741.</a></li><li><a class="nounderline abstract_t">Woodside KJ, Townsend CM Jr, Mark Evers B. Current management of gastrointestinal carcinoid tumors. J Gastrointest Surg 2004; 8:742.</a></li><li><a class="nounderline abstract_t">Warner RR, Mani S, Profeta J, Grunstein E. Octreotide treatment of carcinoid hypertensive crisis. Mt Sinai J Med 1994; 61:349.</a></li><li><a class="nounderline abstract_t">Davì MV, Bodei L, Francia G, et al. Carcinoid crisis induced by receptor radionuclide therapy with 90Y-DOTATOC in a case of liver metastases from bronchial neuroendocrine tumor (atypical carcinoid). J Endocrinol Invest 2006; 29:563.</a></li><li><a class="nounderline abstract_t">Majeed F, Porter TR, Tarantolo S, et al. Carcinoid crisis and reversible right ventricular dysfunction after embolization in untreated carcinoid syndrome. Eur J Echocardiogr 2007; 8:386.</a></li><li><a class="nounderline abstract_t">Gillams A, Cassoni A, Conway G, Lees W. Radiofrequency ablation of neuroendocrine liver metastases: the Middlesex experience. Abdom Imaging 2005; 30:435.</a></li><li><a class="nounderline abstract_t">Kharrat HA, Taubin H. Carcinoid crisis induced by external manipulation of liver metastasis. J Clin Gastroenterol 2003; 36:87.</a></li><li><a class="nounderline abstract_t">Vaughan DJ, Brunner MD. Anesthesia for patients with carcinoid syndrome. Int Anesthesiol Clin 1997; 35:129.</a></li><li><a class="nounderline abstract_t">Gates J, Hartnell GG, Stuart KE, Clouse ME. Chemoembolization of hepatic neoplasms: safety, complications, and when to worry. Radiographics 1999; 19:399.</a></li><li><a class="nounderline abstract_t">Lewis MA, Jaramillo S, Roberts L, et al. Hepatic artery embolization for neuroendocrine tumors: postprocedural management and complications. Oncologist 2012; 17:725.</a></li><li><a class="nounderline abstract_t">Kinney MA, Warner ME, Nagorney DM, et al. Perianaesthetic risks and outcomes of abdominal surgery for metastatic carcinoid tumours. Br J Anaesth 2001; 87:447.</a></li><li><a class="nounderline abstract_t">Veall GR, Peacock JE, Bax ND, Reilly CS. Review of the anaesthetic management of 21 patients undergoing laparotomy for carcinoid syndrome. Br J Anaesth 1994; 72:335.</a></li><li><a class="nounderline abstract_t">Boudreaux JP, Klimstra DS, Hassan MM, et al. The NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the Jejunum, Ileum, Appendix, and Cecum. Pancreas 2010; 39:753.</a></li><li><a class="nounderline abstract_t">Ramage JK, Davies AH, Ardill J, et al. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours. Gut 2005; 54 Suppl 4:iv1.</a></li><li><a class="nounderline abstract_t">Wonn SM, Ratzlaff AN, Pommier SJ, et al. A prospective study of carcinoid crisis with no perioperative octreotide. Surgery 2022; 171:88.</a></li><li><a class="nounderline abstract_t">Condron ME, Pommier SJ, Pommier RF. Continuous infusion of octreotide combined with perioperative octreotide bolus does not prevent intraoperative carcinoid crisis. Surgery 2016; 159:358.</a></li><li><a class="nounderline abstract_t">Kwon DH, Paciorek A, Mulvey CK, et al. Periprocedural Management of Patients Undergoing Liver Resection or Embolotherapy for Neuroendocrine Tumor Metastases. Pancreas 2019; 48:496.</a></li><li><a class="nounderline abstract_t">Guo LJ, Tang CW. Somatostatin analogues do not prevent carcinoid crisis. Asian Pac J Cancer Prev 2014; 15:6679.</a></li></ol></div><div id="topicVersionRevision">Topic 16638 Version 50.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10080850" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Carcinoid tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2168286" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Detection of somatostatin receptors in surgical and percutaneous needle biopsy samples of carcinoids and islet cell carcinomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2427948" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10080605" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23936548" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Above-Label Doses of Octreotide-LAR in Patients With Metastatic Small Intestinal Carcinoid Tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8977344" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Treatment of the carcinoid syndrome with the longacting somatostatin analogue lanreotide: a prospective study in 39 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10473972" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Ultra-high-dose lanreotide treatment in patients with metastatic neuroendocrine gastroenteropancreatic tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10561168" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Efficacy and safety of prolonged-release lanreotide in patients with gastrointestinal neuroendocrine tumors and hormone-related symptoms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10679645" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Treatment of carcinoid syndrome: a prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11095353" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : The antitumoral effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12860945" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors--the International Lanreotide and Interferon Alfa Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21585408" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Long-term results of treatment of malignant carcinoid syndrome with prolonged release Lanreotide (Somatuline Autogel).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27214300" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : EVALUATION OF LANREOTIDE DEPOT/AUTOGEL EFFICACY AND SAFETY AS A CARCINOID SYNDROME TREATMENT (ELECT): A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29038234" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Patient-Reported Symptom Control of Diarrhea and Flushing in Patients with Neuroendocrine Tumors Treated with Lanreotide Depot/Autogel: Results from a Randomized, Placebo-Controlled, Double-Blind and 32-Week Open-Label Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21451455" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : A review of systemic and liver-directed therapies for metastatic neuroendocrine tumors of the gastroenteropancreatic tract.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19704057" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25014687" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Lanreotide in metastatic enteropancreatic neuroendocrine tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10940692" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Hepatic arterial chemoembolization in the management of advanced digestive endocrine tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16508629" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Selective hepatic artery embolization for treatment of patients with metastatic carcinoid and pancreatic endocrine tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12967136" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Hepatic artery embolization and chemoembolization for treatment of patients with metastatic carcinoid tumors: the M.D. Anderson experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9840528" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Liver embolizations of patients with malignant neuroendocrine gastrointestinal tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18618495" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Radioembolization with selective internal radiation microspheres for neuroendocrine liver metastases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20205229" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Radioembolization with yttrium microspheres for neuroendocrine tumour liver metastases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27918724" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Telotristat Ethyl, a Tryptophan Hydroxylase Inhibitor for the Treatment of Carcinoid Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27918724" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Telotristat Ethyl, a Tryptophan Hydroxylase Inhibitor for the Treatment of Carcinoid Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27918724" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Telotristat Ethyl, a Tryptophan Hydroxylase Inhibitor for the Treatment of Carcinoid Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6191217" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Effects of leukocyte interferon on clinical symptoms and hormone levels in patients with mid-gut carcinoid tumors and carcinoid syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10235222" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Combination therapy with octreotide and alpha-interferon: effect on tumor growth in metastatic endocrine gastroenteropancreatic tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : SWOG S0518: Phase III prospective randomized comparison of depot octreotide plus interferon alpha-2b versus depot octreotide plus bevacizumab (NSC #704865) in advanced, poor prognosis carcinoid patients (NCT00569127)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9849494" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Effects of ondansetron on gastrointestinal symptoms in carcinoid syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23675671" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Ondansetron for diarrhea associated with neuroendocrine tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30171068" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Oral Ondansetron Offers Effective Antidiarrheal Activity for Carcinoid Syndrome Refractory to Somatostatin Analogs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17298762" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Bile Acid malabsorption.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26245686" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Symptomatic Control of Neuroendocrine Tumours with Everolimus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21169474" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Control of carcinoid syndrome with everolimus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22119496" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20194865" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : 90Y-edotreotide for metastatic carcinoid refractory to octreotide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29878866" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Health-Related Quality of Life in Patients With Progressive Midgut Neuroendocrine Tumors Treated With 177Lu-Dotatate in the Phase III NETTER-1 Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26170123" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Variation in Cardiac Screening and Management of Carcinoid Heart Disease in the UK and Republic of Ireland.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15358337" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Current management of gastrointestinal carcinoid tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7969229" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Octreotide treatment of carcinoid hypertensive crisis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16840837" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Carcinoid crisis induced by receptor radionuclide therapy with 90Y-DOTATOC in a case of liver metastases from bronchial neuroendocrine tumor (atypical carcinoid).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17011239" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Carcinoid crisis and reversible right ventricular dysfunction after embolization in untreated carcinoid syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15759207" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Radiofrequency ablation of neuroendocrine liver metastases: the Middlesex experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12488725" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Carcinoid crisis induced by external manipulation of liver metastasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9444534" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Anesthesia for patients with carcinoid syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10194787" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Chemoembolization of hepatic neoplasms: safety, complications, and when to worry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22511263" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Hepatic artery embolization for neuroendocrine tumors: postprocedural management and complications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11517130" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Perianaesthetic risks and outcomes of abdominal surgery for metastatic carcinoid tumours.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8130054" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Review of the anaesthetic management of 21 patients undergoing laparotomy for carcinoid syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20664473" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : The NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the Jejunum, Ileum, Appendix, and Cecum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15888809" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34226047" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : A prospective study of carcinoid crisis with no perioperative octreotide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26603846" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Continuous infusion of octreotide combined with perioperative octreotide bolus does not prevent intraoperative carcinoid crisis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30946246" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Periprocedural Management of Patients Undergoing Liver Resection or Embolotherapy for Neuroendocrine Tumor Metastases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25169508" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Somatostatin analogues do not prevent carcinoid crisis.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
